1-8 of 8
Jeffrey Settleman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA2-1: Modeling drug sensitivity and resistance in human tumor-derived cell lines

Jeffrey Settleman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): IA2-1.
https://doi.org/10.1158/1078-0432.TCMUSA10-IA2-1
Published: 02 February 2016
View article titled, Abstract IA2-1: Modeling drug sensitivity and resistance in human tumor-derived cell lines
Journal Articles

Abstract B22: Potential combinatorial strategies to overcome drug resistance in BRAF-mutant melanoma

Nicholas A. Dompe, Eva Lin, Jing Peng, Grace Chan, Grace Chan, Grace Chan, Janet Tien, Mark Merchant, Richard Bourgon, Jeffrey Settleman, Timothy Wilson, Richard M. Neve
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): B22.
https://doi.org/10.1158/1557-3265.PMS14-B22
Published: 13 February 2015
View article titled, Abstract B22: Potential combinatorial strategies to overcome drug resistance in BRAF-mutant melanoma
Journal Articles

Modeling drug sensitivity and resistance in human tumor-derived cell lines

Jeffrey Settleman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): PL1-1.
https://doi.org/10.1158/DIAG-10-PL1-1
Published: 15 August 2014
View article titled, Modeling drug sensitivity and resistance in human tumor-derived cell lines
Journal Articles

Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling

Ryan B. Corcoran, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino-Kenudson, Jeffrey A. Engelman, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle, Dora Dias-Santagata
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR8.
https://doi.org/10.1158/1078-0432.MECHRES-PR8
Published: 04 March 2013
View article titled, Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling
Open the PDF for Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling in another window
Journal Articles

Activation of PI3K Signaling in Merkel Cell Carcinoma

Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias-Santagata
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1227–1236.
https://doi.org/10.1158/1078-0432.CCR-11-2308
Published: 01 March 2012
View article titled, Activation of PI3K Signaling in Merkel Cell Carcinoma
Open the PDF for Activation of PI3K Signaling in Merkel Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Tan Min Chin, Margaret P. Quinlan, Anurag Singh, Lecia V. Sequist, Thomas J. Lynch, Daniel A. Haber, Sreenath V. Sharma, Jeffrey Settleman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6867–6876.
https://doi.org/10.1158/1078-0432.CCR-08-0093
Published: 03 November 2008
View article titled, Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
Open the PDF for Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment in another window
Journal Articles

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Tim G. Eisen, Jeffrey Engelman, Glenwood D. Goss, Daniel A. Haber, John V. Heymach, Pasi A. Jänne, Bruce E. Johnson, David H. Johnson, Rogerio C. Lilenbaum, Matthew Meyerson, Alan B. Sandler, Lecia V. Sequist, Jeffrey Settleman, Kwok-Kin Wong, Carol S. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4365s–4371s.
https://doi.org/10.1158/1078-0432.CCR-06-1005
Published: 20 July 2006
View article titled, Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents
Open the PDF for Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents in another window
Journal Articles

“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation

Sreenath V. Sharma, Michael A. Fischbach, Daniel A. Haber, Jeffrey Settleman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4392s–4395s.
https://doi.org/10.1158/1078-0432.CCR-06-0096
Published: 20 July 2006
View article titled, “Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation
Open the PDF for “Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation in another window